MDxHealth SA ADR (NASDAQ:MDXH) — Market Cap & Net Worth
Market Cap & Net Worth: MDxHealth SA ADR (MDXH)
MDxHealth SA ADR (NASDAQ:MDXH) has a market capitalization of $111.46 Million ($111.46 Million) as of September 21, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #18896 globally and #4373 in its home market, demonstrating a -6.06% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying MDxHealth SA ADR's stock price $2.17 by its total outstanding shares 51364520 (51.36 Million). Also see how large is MDxHealth SA ADR's balance sheet for a full breakdown of the balance sheet.
MDxHealth SA ADR Market Cap History: 2015 to 2026
MDxHealth SA ADR's market capitalization history from 2015 to 2026. Data shows change from $2.23 Billion to $32.36 Million (-24.48% CAGR). Also see MDXH cash generation efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
MDxHealth SA ADR is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.65 Trillion | 0.00% | #537 of 976 |
|
NASDAQ Composite
IXIC
|
$42.12 Trillion | 0.00% | #1832 of 3165 |
Weight: MDxHealth SA ADR's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
MDxHealth SA ADR Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how MDxHealth SA ADR's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check MDxHealth SA ADR stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.70x
MDxHealth SA ADR's market cap is 1.70 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.45 Billion | $29.87 Million | -$13.17 Million | 82.03x | N/A |
| 2017 | $2.20 Billion | $40.51 Million | -$12.29 Million | 54.40x | N/A |
| 2018 | $1.00 Billion | $28.34 Million | -$32.45 Million | 35.35x | N/A |
| 2019 | $565.01 Million | $11.79 Million | -$43.10 Million | 47.94x | N/A |
| 2020 | $518.78 Million | $18.46 Million | -$28.66 Million | 28.10x | N/A |
| 2021 | $534.19 Million | $22.24 Million | -$29.00 Million | 24.02x | N/A |
| 2022 | $51.36K | $37.05 Million | -$44.04 Million | 0.00x | N/A |
| 2023 | $202.38 Million | $70.19 Million | -$43.10 Million | 2.88x | N/A |
| 2024 | $121.73 Million | $90.05 Million | -$38.07 Million | 1.35x | N/A |
| 2025 | $183.37 Million | $107.88 Million | -$33.52 Million | 1.70x | N/A |
Competitor Companies of MDXH by Market Capitalization
Companies near MDxHealth SA ADR in the global market cap rankings as of September 21, 2026. Review tangible equity quality of MDxHealth SA ADR to assess the quality of the company's equity after excluding intangible assets.
Key companies related to MDxHealth SA ADR by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #89 globally with a market cap of $224.59 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #160 globally with a market cap of $149.61 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #475 globally with a market cap of $57.91 Billion USD ( CN¥395.72 Billion CNY).
- Natera Inc (NASDAQ:NTRA): Ranked #578 globally with a market cap of $47.01 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #89 | Thermo Fisher Scientific Inc | NYSE:TMO | $224.59 Billion | $651.45 |
| #160 | Danaher Corporation | NYSE:DHR | $149.61 Billion | $211.81 |
| #475 | WuXi AppTec Co Ltd | SHG:603259 | $57.91 Billion | CN¥160.00 |
| #578 | Natera Inc | NASDAQ:NTRA | $47.01 Billion | $369.39 |
MDxHealth SA ADR Historical Marketcap From 2015 to 2026
Between 2015 and today, MDxHealth SA ADR's market cap moved from $2.23 Billion to $ 32.36 Million, with a yearly change of -24.48%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $32.36 Million | -82.35% |
| 2025 | $183.37 Million | +50.63% |
| 2024 | $121.73 Million | -39.85% |
| 2023 | $202.38 Million | +393900.00% |
| 2022 | $51.36K | -99.99% |
| 2021 | $534.19 Million | +2.97% |
| 2020 | $518.78 Million | -8.18% |
| 2019 | $565.01 Million | -43.59% |
| 2018 | $1.00 Billion | -54.55% |
| 2017 | $2.20 Billion | -10.06% |
| 2016 | $2.45 Billion | +9.66% |
| 2015 | $2.23 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of MDxHealth SA ADR was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $111.46 Million USD |
| MoneyControl | $111.46 Million USD |
| MarketWatch | $111.46 Million USD |
| marketcap.company | $111.46 Million USD |
| Reuters | $111.46 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About MDxHealth SA ADR
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the… Read more